Drug Profile
Research programme: GAIM monomers - NeuroPhage Pharmaceuticals
Alternative Names: NPT-005Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator NeuroPhage Pharmaceuticals
- Developer Proclara Biosciences
- Class
- Mechanism of Action Amyloid beta-protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Amyloidosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Amyloidosis in USA
- 13 May 2013 Early research in Amyloidosis in USA (unspecified route)